CL0820R

Human Chromogranin A CLIA Kit

Description

The EDI™ Human Chromogranin A CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative determination of human chromogranin A (CgA) levels in serum using the ECL100 or ECL25 Immunoassay analyzer. This test may be used as an aid for detecting patients with pheochromocytoma and neuroendocrine tumors (such as carcinoids, etc.).
​​​​​​​
For research use only. Not for use in diagnostics procedures.

Background


​​​​​​​The EDI™ Human Chromogranin A Chemiluminescence Immunoassay (CLIA) kit is designed, developed, and produced for the quantitative measurement of human CgA level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of CgA. Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with streptavidin coated magnetic particles and biotinylated anti-CgA polyclonal antibody. After an incubation period, a wash step is introduced and an acridinium ester conjugated anti-CgA monoclonal antibody is added to each reaction vessel. The magnetic particles capture the biotin antibody as well as an immuno complex in the form of “magnetic particles–biotin CgA antibody–CgA–acridinium ester CgA antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then, trigger solutions are added to the reaction vessel and light emission is measured with the ECL100 or ECL25 analyzer. The relative light units (RLU) are proportional to the concentration of a CgA in the sample. The amount of analyte in the sample is determined from a built-in multi-point calibration curve and reported in serum CgA concentration.

Specifications

Catalog no. CL0820R
Target Chromogranin A
Species Human
Method Sandwich CLIA
Tests Per Kit 100 tests
Detection Flash AE Chemiluminescence
Sensitivity / LLOD 3.2 ng/mL
Dynamic Range 0 - 5000 ng/mL
Total Incubation Time < 30 min
Sample Type Serum
Sample Volume 20 µL
Storage Temperature 2-8 °C

Selected Literature


1. Rafael Molina, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biol. 2011; 32:13–22
2. S L Burgio, V Conteduca, et al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocrine-Related Cancer 2014; 21, 487–493
3. Nikou, G. C., Lygidakis, N. J., Toubanakis, C., Pavlatos, S., Tseleni-Balafouta, S., Giannatou, E., Mallas, E., &Safioleas, M. (2005). Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepato-gastroenterology, 52(63), 731–741.
4. Wu, J. T., Erickson, A. J., Tsao, K. C., Wu, T. L., & Sun, C. F. (2000). Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Annals of clinical and laboratory science, 30(2), 175–178.
For research use only. Not for use in diagnostics procedures.